Recent advances in natriuretic peptides in congestive heart failure

Guido Boerrigter, John C. Burnett

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

Original languageEnglish (US)
Pages (from-to)643-652
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number6
StatePublished - Jun 2004


  • Cyclic guanosine monophosphate
  • Heart failure
  • Natriuretic peptides
  • Nesiritide
  • Neurohumoral activation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Recent advances in natriuretic peptides in congestive heart failure'. Together they form a unique fingerprint.

Cite this